RADNOR, Pa., Sept. 19, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and life-threatening infectious diseases, today announced the presentation of data at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago on September 17 and 18, 2011. PolyMedix was selected by ICAAC as part of a select group to participate in a special oral session that featured new antimicrobial agents in development. In addition, PolyMedix presented data, in poster format, on both its lead defensin-mimetic antibiotic compound, PMX-30063 and other new antibiotic compounds.
